View Item 

Show simple item record

Prevalence of hearing and vestibular loss in cystic fibrosis patients exposed to aminoglycosides
dc.contributor.authorHandelsman, Jaynee A.
dc.contributor.authorNasr, Samya Z.
dc.contributor.authorPitts, Crystal
dc.contributor.authorKing, William M.
dc.date.accessioned2017-10-05T18:19:35Z
dc.date.available2018-12-03T15:34:03Zen
dc.date.issued2017-09
dc.identifier.citationHandelsman, Jaynee A.; Nasr, Samya Z.; Pitts, Crystal; King, William M. (2017). "Prevalence of hearing and vestibular loss in cystic fibrosis patients exposed to aminoglycosides." Pediatric Pulmonology 52(9): 1157-1162.
dc.identifier.issn8755-6863
dc.identifier.issn1099-0496
dc.identifier.urihttps://hdl.handle.net/2027.42/138372
dc.description.abstractAimCystic Fibrosis (CF) patients frequently use aminoglycosides (AGS) to treat CF exacerbation due to colonization with Pseudomonas aeruginosa. Although AGS can cause vestibular and auditory sensory losses that can negatively impact quality of life, little is known about the prevalence of vestibular loss in this population. The aim of this study was to determine the prevalence of hearing loss and/or vestibular dysfunction in CF patients treated with AGS.MethodsThe relationship between hearing status and vestibular status was also investigated. Hearing was determined to be normal or abnormal based on pure tone air and bone conduction thresholds. Vestibular outcome was divided into four categories; normal, non‐lateralized vestibular dysfunction, unilateral loss, and bilateral loss based on results of post head shaking testing, positional and positioning testing, bithermal calorics, sinusoidal, and rotational step testing.ResultsOf our cohort of 71 patients, 56 (79%) patients have vestibular system dysfunction while only 15 (21%) have normal vestibular system function. Overall, 16 patients (23%) have hearing loss. In considering the relationship between auditory and vestibular function, 12 (17%) demonstrated both normal hearing and normal vestibular function and 13 (18%) have both hearing loss and abnormal vestibular function. Of the 55 (78%) patients with normal hearing, 43 (61%) have vestibular dysfunction, while 3 (4%) of patients with normal vestibular function have hearing loss.ConclusionThese results suggest that monitoring hearing alone is insufficient to detect ototoxicity in CF patients being treated with systemic AGS.
dc.publisherThomson Delmar Learning
dc.publisherWiley Periodicals, Inc.
dc.subject.othervestibular loss
dc.subject.otherototoxicity
dc.subject.otherhearing loss
dc.subject.othercystic fibrosis
dc.subject.otheraminoglycosides
dc.titlePrevalence of hearing and vestibular loss in cystic fibrosis patients exposed to aminoglycosides
dc.typeArticleen_US
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelPediatrics
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/138372/1/ppul23763_am.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/138372/2/ppul23763.pdf
dc.identifier.doi10.1002/ppul.23763
dc.identifier.sourcePediatric Pulmonology
dc.identifier.citedreferenceNick JA, Chacon CS, Brayshaw SJ, et al. Effects of gender and age at diagnosis on disease progression in long‐term survivors of cystic fibrosis. Am J Respir Crit Care Med. 2010; 182: 614 – 626.
dc.identifier.citedreferenceTaylor J, Goodkin HP. Dizziness and vertigo in the adolescent. Otolaryngol Clin North Am. 2011; 44: 309 – 321;vii‐viii.
dc.identifier.citedreferenceValente LM. Assessment techniques for vestibular evaluation in pediatric patients. Otolaryngol Clin North Am. 2011; 44: 273 – 290;vii.
dc.identifier.citedreferenceWiener‐Vacher S. What is useful in vestibular testing ? Oto‐Rhino‐Laryngologica. 2002; 11: 95 – 98.
dc.identifier.citedreferenceWiener‐Vacher SR. Vestibular disorders in children. Int J Audiol. 2008; 47: 578 – 583.
dc.identifier.citedreferenceMulheran MC, Degg S, Burr DW, Morgan DE. Stableforth. Occurrence and risk of cochleotoxicity in cystic fibrosis patients receiving and repeated high doses of aminoglycoside therapy. Antimicrob Agents Chemother. 2001; 45: 2502 – 2509.
dc.identifier.citedreferenceTan HVK, Mulheran M, Knox AJ, Smyth AR. Aminoglycoside prescribing and surveillance in cystic fibrosis. Am J Respir Crit Care Med. 2003; 167: 819 – 823.
dc.identifier.citedreferenceHandelsman JA. Audiologic findings in vestibular toxicity. In: Campbell KCM, ed. Pharmacology and ototoxicity for Audiologists. Clifton Park: Thomson Delmar Learning; 2006; 272 – 286.
dc.identifier.citedreferenceBesier T, Goldbeck L. Growing up with cystic fibrosis: achievement, life satisfaction, and mental health. Qual Life Res. 2012; 21: 1829 – 1835.
dc.identifier.citedreferenceChamnan P, Shine BS, Haworth CS, Bilton D, Adler AI. Diabetes as a determinant of mortality in cystic fibrosis. Diabetes Care. 2010; 33: 311 – 316.
dc.identifier.citedreferenceCohen‐Cymberknoh M, Shoseyov D, Kerem E. Managing cystic fibrosis: strategies that increase life expectancy and improve quality of life. Am J Respir Crit Care Med. 2011; 183: 1463 – 1471.
dc.identifier.citedreferenceSimmonds NJ, D’Souza L, Roughton M, Alton EW, Davies JC, Hodson ME. Cystic fibrosis and survival to 40 years: a study of cystic fibrosis transmembrane conductance regulator function. Eur Respir J. 2011; 37: 1076 – 1082.
dc.identifier.citedreferenceCystic Fibrosis Foundation [US]. https://www.cff.org/What‐is‐CF/About‐Cystic‐Fibrosis/. Accessed 12.17.2016.
dc.identifier.citedreferenceAhmed RM, Hannigan IP, MacDougall HG, Chan RC, Halmagyi GM. Gentamicin ototoxicity: a 23‐year selected case series of 103 patients. Med J Aust. 2012; 196: 701 – 704.
dc.identifier.citedreferenceBlack FO, Gianna‐Poulin C, Pesznecker SC. Recovery from vestibular ototoxicity. Otol Neurotol. 2001; 22: 662 – 671.
dc.identifier.citedreferenceBlack FO, Pesznecker S, Stallings V. Permanent gentamicin vestibulotoxicity. Otol Neurotol. 2004; 25: 559 – 569.
dc.identifier.citedreferenceIshiyama G, Ishiyama A, Kerber K, Baloh RW. Gentamicin ototoxicity: clinical features and the effect on the human vestibulo‐ocular reflex. Acta Otolaryngol. 2006; 126: 1057 – 1061.
dc.identifier.citedreferenceHandelsman JA. Vestibular ototoxicity. Perspectives on Hearing and Hearing Disorders: Research and Diagnostics. 2005; 9: 26 – 30.
dc.identifier.citedreferenceBrandt T. Bilateral vestibulopathy revisited. Eur J Med Res. 1996; 1: 361 – 368.
dc.identifier.citedreferencePrayle A, Watson A, Fortnum H, Smyth A. Side effects of aminoglycosides on the kidney, ear and balance in cystic fibrosis. Thorax. 2010; 65: 654 – 658.
dc.identifier.citedreferencePrayle A, Smyth AR. Aminoglycoside use in cystic fibrosis: therapeutic strategies and toxicity. Curr Opin Pulm Med. 2010; 16: 604 – 610.
dc.identifier.citedreferenceO’Reilly R, Grindle C, Zwicky EF, Morlet T. Development of the vestibular system and balance function: differential diagnosis in the pediatric population. Otolaryngol Clin North Am. 2011; 44: 251 – 271:vii.
dc.identifier.citedreferenceAl‐Malky G, Dawson SJ, Sirimanna T, Bagkeris E, Suri R. High‐frequency audiometry reveals high prevalence of aminoglycoside ototoxicity in children with cystic fibrosis. J Cyst Fibros. 2011; 14: 248 – 254.
dc.identifier.citedreferenceSaiman LM, Anstead M, Mayer‐Hamblett N. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with pseudomonas aeruginosa: a randomized controlled trial. JAMA. 2010; 303: 1707 – 1715.
dc.identifier.citedreferenceMartins LMN, Camargos PAM, Becker HMG, Becker CG, Guimaraes RES. Hearing loss in cystic fibrosis. International Journal of Pediatric Otorhinolaryngology. 2010; 74: 469 – 473.
dc.identifier.citedreferenceBanerjee D, Stableforth D. The treatment of respiratory pseudomonas infection in cystic fibrosis: what drug and which way ? Drugs. 2000; 60: 1053 – 1064.
dc.identifier.citedreferencePressler T, Bohmova C, Conway S, Dumcius S, Hjelte L, Høiby N, et al. Chronic pseudomonas aeruginosa infection definition: EuroCareCF working group report. J Cyst Fibros. 2011; 10: S75 – S78.
dc.identifier.citedreferenceSmyth A. Update on treatment of pulmonary exacerbations in cystic fibrosis. Curr Opin Pulm Med. 2006; 12: 440 – 444.
dc.identifier.citedreferenceWalsh RM, Bath AP, Bance ML. Reversible tobramycin‐induced bilateral high‐frequency vestibular toxicity. ORL J Otorhinolaryngol Relat Spec. 2000; 62: 156 – 159.
dc.identifier.citedreferenceCalder JH, Jacobson GP. Acquired bilateral peripheral vestibular system impairment: rehabilitative options and potential outcomes. J Am Acad Audiol. 2000; 11: 514 – 521.
dc.identifier.citedreferenceAl‐Malky G, Suri R, Dawson SJ, Sirimanna T, Kemp D. Aminoglycoside antibiotics cochleotoxicity in paediatric cystic fibrosis (CF) patients: a study using extended high‐frequency audiometry and distortion product otoacoustic emissions. Int J Audiol. 2011; 50: 112 – 122.
dc.identifier.citedreferenceHennig S, McKay K, Vidmar S, et al. Safety of inhaled (Tobi®) and intravenous tobramycin in young children with cystic fibrosis. J Cyst Fibros. 2014; 13: 428 – 434.
dc.identifier.citedreferenceNakashima T, Teranishi M, Hibi T, Kobayashi M, Umemura M. Vestibular and cochlear toxicity of aminoglycosides‐a review. Acta Oto‐Laryngologica. 2000; 120: 904 – 911.
dc.identifier.citedreferencePrayle A, Watson A, Fortnum H, Smyth A. Side effects of aminoglycosides on the kidney, ear and balance in cystic fibrosis. Thorax. 2010; 65: 654 – 658.
dc.identifier.citedreferenceScott CS, Retsch‐Bogart GZ, Henry MM. Renal failure and vestibular toxicity in an adolescent with cystic fibrosis receiving gentamicin and standard‐dose ibuprofen. Pediatr Pulmonol. 2001; 31: 314 – 316.
dc.identifier.citedreferenceLeigh‐Paffenroth E. Objective measures of ototoxicity. Perspectives on Hearing and Hearing Disorders: Research and Diagnostics. 2005; 9: 10 – 16.
dc.identifier.citedreferenceKonrad‐Martin D, Gordon JS, Reavis KM, Wilmington DJ, Helt WJ, Fausti SA. Audiological monitoring of patients receiving ototoxic drugs. Perspectives on Hearing and Hearing Disorders: Research and Diagnostics. 2005; 9: 17 – 21.
dc.identifier.citedreferenceThomsen J, Friis B, Jensen K, Bak‐Pedersen K, Larsen PK. Tobramycin ototoxicity. Repeated courses of high dosage treatment in children with cystic fibrosis. J Antimicrob Chemother. 1979; 5: 257 – 260.
dc.identifier.citedreferenceScheenstra RJ, Rijntjes E, Tavy DL, Kingma H, Heijerman HG. Vestibulotoxicity as a consequence of systemically administered tobramycin in cystic fibrosis patients. Acta Otolaryngol. 2009; 129: 4 – 7.
dc.identifier.citedreferencePaydarfar JA, Goebel JA. Integrated clinical and laboratory vestibular evaluation. Curr Opin Otolaryngol Head Neck Surg. 2000; 8: 363 – 368.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
ppul23763_am.pdf
Size:
519.3KB
Format:
PDF
View/Open
Name:
ppul23763.pdf
Size:
306.3KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.